investors.biogen.com/news-r...
- Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021
- If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimer’s disease
-Can we say that this is a hope for PSP ? (since both Alzheimer & PSP have so much in common "being taupathies etc..." )
Best regards